Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab's potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates.